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Nephrotoxicity limits the use of cisplatin, a widely used
chemotherapeutic agent for treatment of various
malignancies. Overall, CD4þ T cells mediate cisplatin-induced
renal injury; however, the CD4þCD25þ regulatory T-cell
subset (CD4þCD25þ Treg) has broad suppressive effects on
many different cell types. In this study, we determined
whether CD4þCD25þ Treg cells had protective effects
against cisplatin-induced acute renal injury in nu/nu mice
that lack mature T cells. In these mice, there was marked
attenuation of the decreased survival, renal dysfunction
and tubular injury, renal tumor necrosis factor-a, and
interleukin-1b cytokine levels. Furthermore, renal
macrophage accumulation was reduced in CD4þCD25þ Treg
cell-adoptive transferred nu/nu mice compared with control
mice. Infusion of CD4þCD25þTreg cells into wild-type Balb/c
mice reduced serum blood urea nitrogen and creatinine
levels equivalent to those in nu/nu mice and extended their
survival time after cisplatin injection. In contrast, depletion of
CD4þCD25þ Treg cells in wild-type mice exacerbated kidney
injury after cisplatin administration. Transcription factor
Foxp3-positive cells (Treg cells) were detected in the kidneys
of nu/nu mice after cisplatin injection. Our results suggest
that CD4þCD25þ Treg cells directly affect cisplatin
nephrotoxicity and their modulation represents an additional
treatment strategy.
Kidney International (2010) 78, 1100–1109; doi:10.1038/ki.2010.139;
published online 12 May 2010
KEYWORDS: cisplatin; nephrotoxicity; regulatory T cell
Cisplatin is widely used as a chemotherapeutic agent in
various cancers, including ovarian, head and neck, and germ
cell tumors. However, nephrotoxicity is commonly reported
as an adverse effect of cisplatin.1 Indeed, approximately
25–30% of patients experience renal dysfunction after a single
dose of cisplatin.2 Therefore, it is important to understand
the pathophysiological mechanism responsible for cisplatin
nephrotoxicity for the development of adjunctive therapies to
reduce this side effect.
Recent studies in experimental models have confirmed
that T cells have a pathophysiological role in cisplatin
nephrotoxicity. T cell-deficient nu/nu mice show less kidney
injury and tumor necrosis factor (TNF)-a production after
cisplatin administration when compared with normal mice.
Furthermore, CD4-deficient mice have been found to have a
marked degree of protection from renal dysfunction, which
indicates that CD4þ T cells are the primary T-cell subsets
that mediate cisplatin-induced renal injury.3 However, a
study using a chimeric model conducted by Reeves and
colleagues4 demonstrated that the production of TNF-a,
which is a key cytokine involved in the inflammatory
response during cisplatin nephrotoxicity, is more closely
related to resident kidney cells than bone marrow-derived
immune cells. These two studies demonstrate the complexity
of the mechanism that is potentially important in cisplatin-
induced acute kidney injury well.5 Therefore, it is necessary
to identify a specific target to reduce the toxicity associated
with cisplatin, which will require a novel attempt to suppress
various immune responses by different cell types.
Recently, CD4þCD25þ regulatory T (CD4þCD25þ
Treg) cells have been shown to have a pivotal role in the
maintenance of tolerance in the immune system.6–8 There is a
great deal of convincing evidence that CD4þCD25þ Treg
cells can suppress the development of autoimmune diseases,
such as rheumatoid arthritis,9 multiple sclerosis,10 and
lupus.11 Besides having a role in autoimmune diseases,
CD4þCD25þ Treg cells have regulatory function in the
control of transplantation tolerance,12 tumor immunity,13
allergy,14 and infection.15 These broad suppressive effects in
various studies indicate that CD4þCD25þ Treg cells can
inhibit the function of many different cell types.
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Currently available evidence indicates that CD4þCD25þ
Treg cells can suppress CD4þ T cell-mediated pathology in
the kidneys. For example, it has been shown that
CD4þCD25þ Treg cells inhibit antiglomerular basement
membrane glomerulonephritis, which is a complement-
dependent Th1-predominant mouse model.16 In addition,
the ability of CD4þCD25þ Treg cells to inhibit the innate
immune response has been thoroughly investigated.17 It is
known that macrophages, which are an important compo-
nent of innate immunity, are strongly related to the
pathogenesis of various renal diseases. By migrating to the
kidney, macrophages can contribute to tissue damage and
their production of proinflammatory cytokines eventually
progresses to renal failure.18 Recent studies have suggested
that CD4þCD25þ Treg cells can modulate macrophages by
inhibiting their activation, leading to reduced glomerular and
interstitial injury in adriamycin nephropathy.19
In this study, we evaluated CD4þCD25þ Treg cells to
determine whether they could attenuate cisplatin-induced
nephrotoxicity by suppressing their effect on innate immune
reaction. To examine the effects of CD4þCD25þ Treg cells,
we used the CD4þCD25þ Treg-cell adoptive transfer or
depletion methods in T cell-deficient nude mice (nu/nu) and
wild-type (WT) Balb/c mice and evaluated survival, kidney
function, histology, and cytokine expression after cisplatin
administration. In addition, we sought to examine the
migration of Foxp3-positive cells into the kidney after
cisplatin injection.
RESULTS
Adoptive transfer of CD4þCD25þ Treg cells improved the
survival of nu/nu mice
All mice received a single dose of cisplatin at 40 mg/kg and
were then evaluated for 96 h. At 72 h after cisplatin injection,
all Balb/c mice were dead, whereas 15 of the 16 nu/nu mice
were still alive (Figure 1a). The reduced early mortality in
nu/nu mice observed in this study was similar to the results of
a study conducted by Liu et al.3 found in 2006. On the basis
of this reproductive result, the next series of studies were
conducted. However, nu/nu mice also started to die as more
time passed. In particular, 9 out of 16 nu/nu mice that
received CD4þCD25þ Treg cells were alive at 96 h after the
injection of cisplatin, whereas only 3 out of 16 CD4þCD25
T cell-reconstituted nu/nu mice survived (Figure 1b).
CD4þCD25þ Treg cells attenuated renal dysfunction of
cisplatin-treated mice
Cisplatin causes acute renal injury, which induces an increase
in serum creatinine and blood urea nitrogen (BUN).
Therefore, kidney function was monitored by measuring
the serum creatinine and BUN levels after intraperitoneal
injection of saline or cisplatin. Cisplatin administration led to
the development of acute kidney injury with an increase in
creatinine (saline 0.28±0.05 mg/dl; cisplatin 2.4±0.48 mg/dl)
and BUN (saline 29±1.8 mg/dl; cisplatin 185±22 mg/dl)
levels being observed within 24 h of cisplatin administration
in WT mice. In contrast, nu/nu mice that received cisplatin
showed significant attenuation of the increase in creatinine
(0.3±0.04 mg/dl) and BUN (38±4.4 mg/dl) levels when
compared with WT mice. There were no differences among
nu/nu mice groups at 24 h; however, 48 h after the
administration of cisplatin, increases in the serum creatinine
and BUN levels were observed in nu/nu mice and
CD4þCD25 T cell-adoptive transferred nu/nu mice.
Furthermore, significant attenuation of cisplatin-medicated
renal dysfunction was observed in CD4þCD25þ Treg cell-
adoptive transferred nu/nu mice (Figure 2). However, the
transfer of CD4þCD25 T cell into nu/nu mice could
not exacerbate renal dysfunction, which contradicts the
earlier observations made by Rabb and co-workers.3 In
particular, the studies conducted by Rabb et al. injected
approximately 3 106 T cells into nu/nu mice 3 weeks before
cisplatin administration, whereas we transferred B1 106
CD4þCD25 T cells into nu/nu mice 10 days before cisplatin
injection. The composition and number of T cells reported by
Rabb et al. were different from those observed in this study.
Therefore, we cannot exclude the possibility that other T-cell
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Figure 1 | Survival in cisplatin-treated mice. All mice received a
single dose of cisplatin intraperitoneally (40mg/kg body weight)
and were followed up for up to 96 h. (a) nu/nu Mice had a 69%
survival rate, whereas all Balb/c mice expired (***Po0.001 vs Balb/c;
n¼ 16 to 21). (b) nu/nu Mice were reconstituted by tail
intravenous injection with 1 106 CD4þCD25 T cells or
CD4þCD25þ Treg cells 10 days before cisplatin administration.
CD4þCD25þ Treg cell-reconstituted mice had a longer survival
time than did the other mice (***Po0.001 vs cisplatin; n¼ 16).
Treg, T regulatory cell.
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subsets have a synergistic pathological effect with CD4þCD25
T cells on cisplatin-induced nephrotoxicity or that the number
of transferred CD4þCD25 T cells and time allowed for
expansion in the lymphoid organs are not sufficient to reveal
the pathological effects of CD4þCD25 T cells.
Adoptive transfer of CD4þCD25þ Treg cells reduced renal
injury in nu/nu mice
The degree of renal tubular injury in saline, CD4þCD25 T,
and CD4þCD25þ Treg cell-treated groups was observed at
48 h after cisplatin administration. nu/nu Mice that received
CD4þCD25þ Treg cells had less renal injury than did nu/nu
mice that received saline. However, nu/nu mice that received
CD4þCD25 T cells and nu/nu mice showed extensive renal
injury at 48 h after cisplatin injection (Figure 3).
Adoptive transfer of CD4þCD25þ Treg cells reduced
macrophage infiltration in the kidneys of mice
Macrophages were found in the interstitium of kidney
sections in the cisplatin group of mice and the CD4þCD25
group of mice. At 48 h after cisplatin administration, more
F4/80-positive macrophages were observed in the cisplatin
group of mice and the CD4þCD25 group of mice.
Conversely, F4/80-positive macrophages were rarely detected
in the CD4þCD25þ group of mice (Figure 4).
Effect of CD4þCD25þ T cells on proinflammatory cytokines
in cisplatin nephrotoxicity
To investigate proinflammatory molecules generated by
cisplatin renal injury, cytokine levels of TNF-a and inter-
leukin (IL)-1b were measured at 48 h after cisplatin
administration. Cisplatin-treated mice showed increased
levels of TNF-a and IL-1b at 48 h after cisplatin injection.
However, nu/nu mice that received CD4þCD25þ Treg cells
showed reduced TNF-a (saline 2200±180 pg/mg; cisplatin
4100±290 pg/mg; CD4þCD25 4531±526.5 pg/mg;
CD4þCD25þ 3181±85.20 pg/mg) and IL-1b (saline 1200±
160 pg/mg; cisplatin 3972±363.8 pg/mg; CD4þCD25
3668±515.5 pg/mg; CD4þCD25þ 1969±63.82 pg/mg)
levels (Figure 5).
Effect of infused CD4þCD25þ Treg cells on cisplatin
nephrotoxicity in Balb/c mice
After investigating the protective effects of CD4þCD25þ
Treg cells on cisplatin nephrotoxicity in nu/nu mice, we tested
whether infused CD4þCD25þ Treg cells might have had a
protective role in cisplatin-induced renal injury. Approxi-
mately 3 106 CD4þCD25þ Treg cells were injected into
Balb/c mice through the tail vein. At 10 days after injection of
the CD4þCD25þ Treg cells, mice received a single dose of
cisplatin at a concentration of 25 mg/kg. Interestingly, mice
infused with CD4þCD25þ Treg cells showed prolonged
survival times and attenuations of the serum creatinine and
BUN levels (Figure 6).
Effect of CD4þCD25þ Treg cell depletion on cisplatin
nephrotoxicity in Balb/c mice
A dose of 0.25 mg of anti-CD25 antibody was injected daily
for 3 days before cisplatin administration. All Balb/c mice
received a single dose of cisplatin at 25 mg/kg. There were no
#
Cr
ea
tin
in
e 
(m
g/d
l)
Cr
ea
tin
in
e 
(m
g/d
l)
Bu
n 
(m
g/d
l)
Bu
n 
(m
g/d
l)
4
3
2
1
0
24 h
48 h 48 h
***2.0
1.5
1.0
0.5
0.0
*
***
**
24 h
Saline (Balb/c)
Cisplatin (Balb/c)
#
250
200
50
0
150
100
200
50
0
150
100
Saline
Saline
Cisplatin
CD4+CD25 –
CD4+CD25 +
Saline (Balb/c)
Cisplatin (Balb/c)
Cisplatin
CD4+CD25 –
CD4+CD25 +
Figure 2 | Effect of CD4þCD25þ Treg cells on renal dysfunction in mice. nu/nu Mice were reconstituted by tail intravenous injection
with 1 106 CD4þCD25 or CD4þCD25þ T cells 10 days before cisplatin administration. Balb/c mice: saline treatment alone (saline
(Balb/c)); cisplatin treatment alone (cisplatin (Balb/c)). nu/nu Mice: saline treatment alone (saline); cisplatin treatment alone (cisplatin);
transferred CD4þCD25 T-cell and cisplatin treatment (CD4þCD25); transferred CD4þCD25þ Treg cell and cisplatin treatment
(CD4þCD25þ ). Creatinine and BUN levels were measured at 24 and 48 h, respectively, after saline or cisplatin injection. Changes in
creatinine (creatinine 48 h: saline 0.30±0.04mg/dl; cisplatin 1.2±0.13mg/dl; CD4þCD25þ 0.79±0.09mg/dl) and BUN (BUN 48 h: saline
23±2.4mg/dl; cisplatin 140±15mg/dl; CD4þCD25þ 80±9.4mg/dl) levels were measured (*Po0.05, **Po0.01, ***Po0.001, #Po0.001 vs
cisplatin, two-tailed paired t-test; n¼ 6 to 7). BUN, blood urea nitrogen; Treg, T regulatory cell.
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differences among groups at 24 and 48 h; however, 72 h after
cisplatin injection, increases in the serum creatinine and
BUN levels were observed in CD4þCD25þ Treg cell-
depleted mice (Figure 7b). Furthermore, exacerbation of
renal injury was observed in CD4þCD25þ Treg cell-depleted
mice at 72 h after cisplatin treatment when compared with
normal Balb/c mice (Figure 7c). CD4þCD25þ Treg cell-
depleted mice also died slightly earlier than did normal Balb/
c mice (Figure 7d), indicating that CD4þCD25þ Treg cells
have a functional role in cisplatin nephrotoxicity.
Assessment of CD4þCD25þ Treg-cell migration into the
kidney upon cisplatin treatment
For assessment of CD4þCD25þ Treg migration into the
kidney, we used Foxp3EGFP mice initially described by
Haribhai et al.20 These mice were derived with a bicistronic
Foxp3 locus that coexpresses the enhanced green fluorescence
protein (EGFP) under control of the endogenous Foxp3
promoter, so that the expression of Foxp3, a key transcrip-
tional factor in CD4þCD25þ Treg cell, could be analyzed in
real time using the EGFP fluorescence signal. To visualize and
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Figure 3 | Effect of CD4þCD25þ Treg cells on renal histology
in mice. Sections of kidney were stained with H&E 48 h after
cisplatin injection. (a) Saline treatment alone (saline); cisplatin
treatment alone (cisplatin); transferred CD4þCD25 T-cell and
cisplatin treatment (CD4þCD25); transferred CD4þCD25þ Treg
cell and cisplatin treatment (CD4þCD25þ ). (b) Tubular injury was
scored using the semi-quantitative evaluation method. The
CD4þCD25þ Treg cell-injected mice had significantly less tubular
injury than did CD4þCD25 T cell-injected mice and cisplatin-
treated control mice (**Po0.01, ***Po0.001 vs cisplatin,
#Po0.001 vs CD4þCD25þ , two-tailed paired t-test; n¼ 4). H&E,
hematoxylin and eosin; Treg, T regulatory cell.
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Figure 4 | Effect of CD4þCD25þ Treg cells on macrophage
infiltration in the kidneys of mice. (a) Accumulation of
macrophages in the kidneys was detected by immunostaining of
F4/80-positive cells at 48 h after cisplatin administration. Saline
treatment alone (saline); cisplatin treatment alone (cisplatin);
transferred CD4þCD25 T-cell and cisplatin treatment
(CD4þCD25); transferred CD4þCD25þ Treg cell and cisplatin
treatment (CD4þCD25þ ). (b) The numbers of F4/80-positive cells
in each section were counted in 10 fields per slide at an original
magnification of  400. Macrophage infiltration was significantly
reduced in CD4þCD25þ Treg cell-reconstituted mice compared
with CD4þCD25 T cell-injected mice and cisplatin-treated
control mice (**Po0.01, ***Po0.001 vs cisplatin, #Po0.001 vs
CD4þCD25þ , two-tailed paired t-test; n¼ 4). Treg, T regulatory cell.
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quantify the degree of Treg migration, confocal microscopy
was used with kidney samples obtained from CD4þCD25þ
Treg-transferred nu/nu mice that were killed at various time
points after cisplatin injection. Our results showed that
Foxp3-positive cells migrated directly to the kidney in mice at
an early time point (Figure 8).
DISCUSSION
In this study, we provide strong evidence that CD4þCD25þ
Treg cells effectively attenuate the adverse effects of cisplatin
nephrotoxicity. Our data showed that the transfer of
CD4þCD25þ Treg cells into nu/nu mice significantly
extended their survival time and reduced renal dysfunction
in a cisplatin-induced renal nephrotoxicity model. In
addition, infiltration of macrophages into the kidney
deceased. Furthermore, renal injury was prevented in
CD4þCD25þ Treg cell-transferred mice. After cisplatin
injection, the levels of proinflammatory cytokine, TNF-a
and IL-1b were increased in all mice, whereas these increases
were attenuated in CD4þCD25þ Treg cell-transferred mice.
An inflammatory basis for cisplatin toxicity was shown
with a role for intercellular adhesion molecule-1, TNF-a, and
other proinflammatory molecules.21 Many studies have
suggested that TNF-a has a key role in cisplatin-induced
nephrotoxicity.21,22 However, there are various cells that can
produce TNF-a in the kidney, which makes understanding
the mechanism responsible for cisplatin nephrotoxicity
difficult. Reeves and colleagues4 demonstrated that TNF-a
is produced by resident kidney cells rather than bone
marrow-derived immune cells. Conversely, recent work by
Rabb et al. demonstrated that T cell-deficient nu/nu mice
have attenuated cisplatin renal injury when compared with
WT mice. Furthermore, reconstitution of T cells into T cell-
deficient nu/nu mice leads to increased renal dysfunction and
TNF-a production in a mouse model, which indicates that
infiltrating CD4þ T cells have a significant role in the
pathogenesis in cisplatin-induced nephrotoxicity.3 Our 96-h
follow-up survival data showed that nu/nu mice started to die
after cisplatin injection, although T cell-deficient nu/nu mice
had a longer survival time than did WT Balb/c mice. These
results indicate that infiltration of T cells is not the only
pathogenic factor in cisplatin-induced nephrotoxicity.
Macrophages have been proposed as important mediators
of injury in most types of primary and secondary human
kidney diseases.23 The degree of macrophage infiltration is a
major parameter used to predict the progression of disease
and the activation of macrophage expressed inflammatory
mediators, including nitric oxide and TNF-a, which are
major pathogenic factors associated with cisplatin nephro-
toxicity. Indeed, a clear association has been shown between
macrophage accumulation and the severity of renal injury.18
In addition, various reports have shown that depletion of
macrophages reduced renal injury.24,25
The suppressive effect of CD4þCD25þ Treg cells on
CD4þCD25 T cell has been well documented. However, the
protection effect of CD4þCD25þ Treg cells in nu/nu mice
after cisplatin administration showed that CD4þCD25þ
Treg cells have a more general immunosuppressive effect in
our mice model. Maloy et al.26 reported that the presence of
Tregs resulted in reduced recruitment of monocyte/macro-
phage to the site of inflammation. In addition, a recent study
has shown that when monocytes were cocultured with
CD4þCD25þ Treg cells, the expression of activating markers
of monocytes such as CD40, CD80, and HLA II were
significantly lower when compared with monocytes that were
cultured in the presence of CD4þCD25 T cells. Moreover,
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Figure 5 |Proinflammatory cytokines in the kidney.
Proinflammatory cytokines in the kidney were measured by ELISA
at 48 h after cisplatin injection. When compared with cisplatin-
treated control mice, the elevation of TNF-a (a; saline 2200±180;
cisplatin 4100±290; CD4þCD25 4531±526.5; CD4þCD25þ
3181±85.20) and IL-1b (b; saline 1200±160; cisplatin 4000±360;
CD4þCD25 3668±515.5; CD4þCD25þ 1969±63.82) was
significantly lower in CD4þCD25þ Treg cell-reconstituted mice.
(**Po0.01, ***Po0.001 vs cisplatin, #Po0.001 vs CD4þCD25þ ,
two-tailed paired t-test; n¼ 4). ELISA, enzyme-linked
immunosorbent assay; IL-1b, interleukin-1b; TNF-a, tumor necrosis
factor-a; Treg, T regulatory cell.
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CD4þCD25þ Treg cells affected the monocyte/macrophage
cytokine profile in response to strong proinflammatory
stimuli, such as lipopolysaccharides.27 Similarly, in a murine
model of burn injury, there was evidence of CD4þCD25þ
Treg cells suppressing innate immune activation by control-
ling TLR (Toll-like receptor)4 and TLR2 responses.17
The results of this study show that the therapeutic efficacy
of CD4þCD25þ Treg cells in murine cisplatin-induced
nephrotoxicity occurs by suppression of the innate immune
pathology. In particular, renal damage and the infiltration of
macrophages in response to cisplatin were significantly
attenuated by the transfer of CD4þCD25þ Treg cells. The
importance of TNF-a in the pathogenesis of cisplatin-
induced renal dysfunction has been well documented.21,28
Although it is known that TNF-a is mainly produced by
resident kidney cells, reduction of the TNF-a level in
CD4þCD25þ Treg-transferred mice clearly indicated that
CD4þCD25þ Treg cells could affect renal TNF-a produc-
tion. A recent report has shown that activation of TLR4
present on renal parenchymal cells triggers an innate immune
response that mediates cisplatin-induced acute renal failure.5
The results presented in a previous study fit with our
researches that mouse CD4þCD25þ Treg cells suppressed
innate immune pathology.
On the basis of the reduction of renal damage after
CD4þCD25þ Treg transfer, we assumed that Tregs migrate
to the kidney after cisplatin injection. CD4þCD25þ Treg
cells arise in the thymus, represent 5–10% of CD4þ T cells in
the periphery, and are distinguished by the expression of
transcription factor Foxp3.29,30 Therefore, we sought to
examine the migration of Foxp3-positive cells into the kidney
after cisplatin injection. Our results showed that Foxp3-
positive cells infiltrated the kidney at an early time point in
nu/nu mice. T-cell trafficking into a target organ is an
important factor for T cell-mediated injury in kidney
diseases. Studies in experimental models have confirmed
that T cells significantly increased in the kidneys of normal
mice after cisplatin administration at 1 h, peaked at 12 h, and
declined by 24 h.3 In this study, CD4þCD25þ Treg cells
migrated to the kidney at an early time point in nu/nu
mice. This indicated that CD4þCD25þ Treg cells could
have a direct interaction with cisplatin-induced renal
inflammation.
Considering the protective effect of renal injury by
transferred CD4þCD25þ Treg cells in nu/nu mice, one
could assume that manipulating CD4þCD25þ Treg cells
could modulate the harmful effects of cisplatin in WT mice.
Thus, we transferred CD4þCD25þ Treg cells into WT mice
or depleted CD4þCD25þ Treg cells in WT mice. We found
that the transfer of CD4þCD25þ Treg cells into WT mice
reduced the adverse effect of cisplatin, whereas depletion of
CD4þCD25þ Treg cells exacerbated kidney injury. These
findings confirm that CD4þCD25þ Treg cells have a
dynamic role in the regulation of cisplatin-induced nephro-
toxicity.
In summary, in this study, we show for the first time the
protective effect of CD4þCD25þ Treg cells on cisplatin-
induced nephrotoxicity in mice. This study indicates that
CD4þCD25þ Treg cells migrate to the kidney and are
directly related to the regulation of cisplatin nephrotoxicity.
Therefore, we believe that understanding CD4þCD25þ Treg
cell function in cisplatin nephrotoxicity might represent
an additional treatment strategy for cisplatin-induced
nephrotoxicity.
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Figure 6 | Effect of infused CD4þCD25þ Treg cells on cisplatin nephrotoxicity in Balb/c mice. Balb/c mice were reconstituted by
intravenous injection with 3 106 CD4þCD25þ T cells 10 days before cisplatin administration. All mice received a single dose of cisplatin or
saline intraperitoneally (25mg/kg body weight). (a) Survival rate and (b) BUN and serum creatinine (b) were measured 24 h after cisplatin
administration. (*Po0.05 vs cisplatin; n¼ 5). BUN, blood urea nitrogen; Treg, T regulatory cell.
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MATERIALS AND METHODS
Mice
Nu/nu male mice (C. Cg-Foxnl-nu/ CrljBg) and their Balb/c
male littermates (6 to 8 weeks of age, weighing 20–25 g) were
purchased from Orient Bio (Seungnam, South Korea).
Foxp3EGFP Balb/c (C. Cg-Foxp3tm2Tch/J) mice were purchased
from The Jackson Laboratory (Bar Harbor, ME, USA).
All mice were kept under pathogen-free conditions with air
conditioning and a 12-h light/dark cycle. In addition, all mice
had free access to food and water during the experiments.
The study was approved by the University of Kyung Hee
Animal Care and Use Committee.
Cell isolation and T-cell reconstitution
CD4þCD25þ Treg and CD4þCD25 T cells were isolated
from the spleens obtained from male Balb/c mice using
magnetic bead separation (CD4þCD25þ regulatory T-cell
kit; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).
Briefly, non-CD4þ T cells were depleted using biotinylated
antibody cocktail and anti-biotin microbeads. CD4þCD25
T cells were positively selected from CD4þCD25þ Treg cells
using PE (phycoerythrin)-labeled anti-CD25 mAb and anti-
PE microbeads. The purity of both populations was
controlled by flow cytometry analysis and routinely reached
490%. nu/nu Mice (1 106 CD4þCD25 T cells or
CD4þCD25þ Treg cells) Balb/c mice (3 106 CD4þCD25þ
Treg cells) were reconstituted by tail intravenous injection
10 days before cisplatin administration.
Induction of acute nephrotoxicity
Cisplatin (cis-diammineplatinum II dichloride; Sigma-
Aldrich, St Louis, MO, USA) was dissolved in 0.9% saline
at a concentration of 1 mg/ml. Mice were administered a
single intraperitoneal injection of either cisplatin (40 or
25 mg/kg mice body weight) or an equal volume of saline.
Mice were killed at 48 (nu/nu mice) or 72 h (Balb/c mice)
after the administration of cisplatin for histology and kidney
cytokine array analysis. All collected mouse kidneys were
either fixed in 4% paraformaldehyde for histology/immuno-
histochemistry or snap-frozen with liquid nitrogen for tissue
cytokine array.
Assessment of renal function and cytokines
Renal function was assessed by measurements of BUN and
serum creatinine using FUJI DRI-CHEM 3500i (Fuji Photo
Film, Tokyo, Japan). To examine the proinflammatory
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by flow cytometry analysis using PE-anti-mouse CD25 and FITC-anti-mouse CD4 (***Po0.001 vs control, n¼ 4). (b) Creatinine and BUN
levels were measured at 24, 48, and 72 h after saline or cisplatin injection. Changes in creatinine and BUN levels were measured (*Po0.05,
**Po0.01 vs cisplatin, n¼ 6). (c) Sections of kidney were stained with H&E 72 h after cisplatin injection. Tubular injury was scored using the
semi-quantitative evaluation method (*Po0.05 vs cisplatin, n¼ 6). (d) Survival data between CD4þCD25þ Treg cells depletion mice and
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cytokines after cisplatin administration, protein levels of TNF-a
and IL-1b were measured in the kidneys using enzyme-linked
immunosorbent assay (ELISA; BD Biosciences, San Diego, CA,
USA). Briefly, snap-frozen kidney tissue was homogenized in a
PRO-PREP protein extraction solution (iNtRON Biotechno-
logy, Seongnam, Korea), and the supernatant was used for
kidney proinflammatory cytokine array. The protein concen-
trations in the supernatants were determined using a BCATH
Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). The
protein levels of cytokines were corrected for the total amount
of protein, and the results were expressed as pg/mg.
Histological examination
Kidney tissue was fixed in 4% paraformaldehyde and then
embedded in paraffin, cut into 5-mm sections, and stained
with hematoxylin and eosin. Three pathologists who were
blinded to the experiments scored the degree of tubular
injury. Renal tubular injury was assessed using a semi-
quantitative score, in which the percentage of cortical tubules
showing epithelial necrosis was assigned a score of 0, none;
1, o10%; 2, 10–25%; 3, 25–75%; 4, 475%.
Immunohistochemical staining of macrophage
To evaluate macrophage infiltration into the kidneys
after cisplatin administration, immunohistochemical staining
for macrophages was performed on paraffin-embedded
kidney tissue. Briefly, after deparaffinization and rehydration,
kidney sections were pressure cooked in an antigen
unmasking solution (Vector Laboratories, Burlingame, CA,
USA) for 3 min and then immersed in 3% hydrogen
peroxide methanol for 30 min to quench the endogenous
peroxidase. After treatment with blocking buffer, the slides
were incubated overnight at 41C with a rat anti-mouse
F4/80 antibody (dilution 1:50; Serotec, Oxford, UK). The
primary antibody was localized using the Vectastain ABC
Elite Kit (Vector Laboratories) according to the manufac-
turer’s instructions, followed by reaction with a 3,30-
diaminobenzidine substrate-chromogen solution kit (Vector
Laboratories). The slides were counterstained with
Harris hematoxylin. The numbers of F4/80-positive cells in
each section were calculated by counting the number of
positively stained cells in 10 fields per slide at a magnification
of  400.
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Image analysis of renal Foxp3-positive cells
To confirm Foxp3EGFP T-cell infiltration into the mouse
kidney after cisplatin administration, CD4þCD25þ T cells
were isolated from the spleens obtained from Foxp3EGFP
Balb/c mice. nu/nu Mice were reconstituted by tail intrave-
nous injection with 1 106 CD4þCD25þ -enriched T cells
10 days before cisplatin administration. CD4þFoxp3EGFP
T cells from the spleen were confirmed by flow cytometry
analysis, using PE-anti-mouse CD4 (BD Biosciences)
(Figure 8a). Mice killed at different time points after cisplatin
injection and kidneys were embedded in optimal cutting
temperature compound (Sakura, Tokyo, Japan) and then cut
into 20-mm sections. The renal tissues were permeabilized in
0.5% Triton X-100 and then incubated with a blocking
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mouse upon killing and then analyzed by FACS. Foxp3EGFP Balb/c mice had 4.4±0.06% CD4þFoxp3EGFP-positive cells; meanwhile, nu/nu
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buffer. Subsequently, the samples were incubated with the
anti-Foxp3 antibody (dilution 1:100; Santa Cruz Biotechno-
logy, Santa Cruz, CA, USA). The slides were exposed to
fluorescein isothiocyanate-labeled secondary antibody (dilu-
tion 1:300; Santa Cruz Biotechnology). Fluorescent images
were captured on a Zeiss LSM5 confocal microscope (Zeiss,
Jena, Germany).
Depletion of CD4þCD25þ T cells in vivo
Anti-mouse CD25 rat IgG1 (anti-CD25; clone PC61) were
generated in-house from hybridomas obtained from
American Type Culture Collection (Manassas, VA, USA).
A dose of 0.25 mg of anti-CD25 antibody was injected for
3 days before cisplatin administration. The efficacy of
CD4þCD25þ Treg cell depletion was confirmed by flow
cytometry analysis, using PE-anti-mouse CD25 and fluor-
escein isothiocyanate-anti-mouse CD4 (Figure 7a).
Statistical analysis
All data are presented as means±s.e.m. Data were compared
by an unpaired, two-tailed t-test for single comparisons or by
ANOVA (analysis of variance) for multiple comparisons.
Kaplan–Meier analysis was used for mouse survival analyses.
Differences were considered to be significant if the P-value
was o0.05.
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